TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20854164

Group type: EXPERIMENTAL
Intervention: NVC intervention program (n = 39)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Original program (n = 67)
Number of subjects: 106
Study: 17925412

Group type: EXPERIMENTAL
Intervention: SBT with CPS (simulation-trained group)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Traditional training (traditionally trained group)
Number of subjects: 62
Study: 15660030

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 600
Study: 11803309

Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC, approximately 10 microg/kg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oral oxycodone (0.2 mg/kg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9972768

Group type: EXPERIMENTAL
Intervention: Flexible Reinforced Laryngeal Mask Airway (FRLMA)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Endotracheal Tube (ET) extubated awake
Number of subjects: 114

Group type: COMPARATOR
Intervention: Endotracheal Tube (ET) extubated deeply anesthetized
Number of subjects: 114
Study: 7576389

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 1.3% soluble pyrophosphate and 1.5% PVM/MA copolymer in a 0.243% sodium fluoride/silica base
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 0.3% triclosan and 2% PVM/MA copolymer in a 0.243% sodium fluoride/silica base
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 0.3% triclosan and 0.75% zinc citrate in a 1.14% sodium monofluorophosphate/silica base
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo dentifrice (0.243% sodium fluoride/silica)
Number of subjects: 0
Study: 2175776

Group type: EXPERIMENTAL
Intervention: Instruction using all teaching variables prescribed in the Tennyson‐Cocchiarella model for concept attainment (Group 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other two groups (Control groups)
Number of subjects: 0
Study: 398127

Group type: EXPERIMENTAL
Intervention: dezocine 10 mg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: dezocine 15 mg
Number of subjects: 61

Group type: COMPARATOR
Intervention: meperidine 100 mg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: dezocine (both doses)
Number of subjects: 61

Group type: COMPARATOR
Intervention: dezocine and meperidine
Number of subjects: 61
Study: 6641092

Group type: EXPERIMENTAL
Intervention: Alinidine (40 mg three times a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31118201

Group type: EXPERIMENTAL
Intervention: Chemotherapy (more frequent and lower doses)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Antiangiogenic agents (lower doses)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Model predictions after 12 weeks of treatment
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Alternative regimens suggested by model simulations
Number of subjects: 4
Study: 30261238

Group type: EXPERIMENTAL
Intervention: Transcatheter heart valve (THV) system
Number of subjects: 941
Study: 27909035

Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Blockade (TEB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unilateral Continuous Paravertebral Blockade (PVB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 24987942

Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids (180 mg eicosapentaenoic acid and 120 mg docosahexaenoic acid in each capsule), daily for 4 months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 22074027

Group type: EXPERIMENTAL
Intervention: Bimaxillary flask (BMF) with silicone wall
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bimaxillary flask (BMF) with stone wall
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Monomaxillary flask with stone wall
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bimaxillary flask (BMF) with acrylic resin retentions and silicone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 19021601

Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg as needed or once daily for 9 weeks
Number of subjects: 1238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1238

Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg as needed
Number of subjects: 1238
Study: 17458576

Group type: EXPERIMENTAL
Intervention: Whole-body cryostimulation at -120 to -140 degrees C during a ten-day training cycle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole-body cryostimulation during training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control training without cryostimulation
Number of subjects: 0
Study: 15913621

Group type: EXPERIMENTAL
Intervention: Amnioinfusion (1000 mL of warmed sterile saline solution)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Control (conventional treatment only)
Number of subjects: 438
Study: 12459525

Group type: EXPERIMENTAL
Intervention: Lithium gluconate ointment dosed at 8%
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 10604553

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg, once daily (n = 97)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Topical levocabastine 200 microg, twice daily (n = 96)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Matched placebo (n = 95)
Number of subjects: 288
Study: 7722163

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg administered by metered-dose inhaler, twice daily)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 1904028

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 721

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 721
Study: 6118717

Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 76
Study: 31126174

Group type: EXPERIMENTAL
Intervention: Self-management education for four sessions lasting 35–40 minutes with a booster phone call
Number of subjects: 110

Group type: COMPARATOR
Intervention: Routine GDM education program
Number of subjects: 110
Study: 27836885

Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/day
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 171
Study: 25475772

Group type: EXPERIMENTAL
Intervention: 0.2% bioadhesive chlorhexidine gel
Number of subjects: 160

Group type: COMPARATOR
Intervention: bioadhesive placebo
Number of subjects: 160
Study: 23663078

Group type: EXPERIMENTAL
Intervention: Viniyoga intervention (yoga practice 5 times per week for 6 months)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Viniyoga intervention (yoga classes)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Viniyoga intervention (home-based yoga sessions)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Viniyoga intervention
Number of subjects: 32
Study: 21827654

Group type: EXPERIMENTAL
Intervention: Family-centered method for early identification of social-emotional and behavioral problems
Number of subjects: 3500

Group type: COMPARATOR
Intervention: Care as usual (control condition)
Number of subjects: 3500
Study: 19473538

Group type: EXPERIMENTAL
Intervention: External shock wave therapy (ESWT) combined with standard care
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 30
Study: 17243107

Group type: EXPERIMENTAL
Intervention: Multi-component smoking cessation intervention (nurse led behavioral/empowerment counseling, nicotine replacement therapy, community health workers)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 0
Study: 15502720

Group type: EXPERIMENTAL
Intervention: C2-monitored regimen (n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: C0-monitored regimen (n=50)
Number of subjects: 100
Study: 12029233

Group type: EXPERIMENTAL
Intervention: Rutkow technique (group A)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Trabucco technique (group B)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Lichtenstein technique (group C)
Number of subjects: 150
Study: 10193877

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (0.75 pmol x kg(‐1) min(‐1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study: 7564097

Group type: EXPERIMENTAL
Intervention: Cellulosic membranes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polyacrylonitrile membranes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cuprophane membranes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complement activated serum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hrC5a
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normal human serum
Number of subjects: 0
Study: 2376386

Group type: EXPERIMENTAL
Intervention: Povidone-iodine solution (5%) applied topically, 2 drops
Number of subjects: 52

Group type: COMPARATOR
Intervention: NaCl solution, 2 drops
Number of subjects: 52
Study: 7387941

Group type: EXPERIMENTAL
Intervention: Midline episiotomy
Number of subjects: 407

Group type: COMPARATOR
Intervention: Mediolateral episiotomy
Number of subjects: 407
Study: 29859498

Group type: EXPERIMENTAL
Intervention: Stress Management (SM)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Cognitive Restructuring (CR)
Number of subjects: 126
Study: 26248789

Group type: EXPERIMENTAL
Intervention: KICk-OFF course (5-day structured education course)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 396
Study: 25436842

Group type: EXPERIMENTAL
Intervention: Alcohol beverage
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control beverage
Number of subjects: 99
Study: 22326237

Group type: EXPERIMENTAL
Intervention: Transdermal rotigotine (up to 16 mg/24h)
Number of subjects: 217
Study: 20386063

Group type: EXPERIMENTAL
Intervention: Music therapy (music group, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 40
Study: 18316526

Group type: COMPARATOR
Intervention: Maribavir alone (400 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Maribavir plus ketoconazole (400 mg)
Number of subjects: 20
Study: 16010245

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) administered during donor operation (IV & Portal flush)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control Group (no NAC)
Number of subjects: 22
Study: 12439090

Group type: EXPERIMENTAL
Intervention: Gymnasts
Number of subjects: 50

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 50
Study: 10826458

Group type: COMPARATOR
Intervention: Ranitidine hydrochloride, 150 mg twice daily
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Lansoprazole, 15 mg once daily
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Lansoprazole, 30 mg once daily
Number of subjects: 353
Study: 9055014

Group type: EXPERIMENTAL
Intervention: Topical squaric acid dibutylester (SADBE) applied weekly for 20 weeks after sensitization with 2% SADBE in acetone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untreated alopecia sites on the same patient
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Topical squaric acid dibutylester (SADBE)
Number of subjects: 20
Study: 1647443

Group type: EXPERIMENTAL
Intervention: Intravenous flumazenil (3 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous diazepam (10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6384072

Group type: EXPERIMENTAL
Intervention: Pindolol (20.0 +/- 3.13 mg/d)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propranolol (125.0 +/- 19.17 mg/d)
Number of subjects: 8
Study: 30673710

Group type: EXPERIMENTAL
Intervention: Interactive computer-based intervention (ICBI)
Number of subjects: 272
Study: 29119300

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Various treatment modalities (including antibiotics, IVIG, psychiatric medications, cognitive behavioral therapy)
Number of subjects: 33
Study: 26700848

Group type: EXPERIMENTAL
Intervention: Chronic maternal hyperoxygenation (CMH) therapy, ≥ 8 hours daily from enrollment until delivery.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Chronic maternal hyperoxygenation (CMH) therapy, > 9 hours daily (n=6).
Number of subjects: 9
Study: 24043665

Group type: EXPERIMENTAL
Intervention: soft study shoes (soft-SS)
Number of subjects: 247

Group type: COMPARATOR
Intervention: hard study shoes (hard-SS)
Number of subjects: 247
Study: 22545816

Group type: EXPERIMENTAL
Intervention: Chronic care model intervention with geriatric in-home assessment every 6 months and tailored care plan.
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1200
Study: 20556802

Group type: EXPERIMENTAL
Intervention: Furosemide, 40 mg intravenous bolus
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Nesiritide, 2 microg/kg intravenous bolus followed by a 0.01 microg/kg/min infusion for 6 hours
Number of subjects: 28

Group type: COMPARATOR
Intervention: Furosemide plus Nesiritide
Number of subjects: 28
Study: 18018468

Group type: EXPERIMENTAL
Intervention: Periodontal surgery (Group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive periodontal therapy (Group B)
Number of subjects: 0
Study: 16361986

Group type: EXPERIMENTAL
Intervention: Current treatments for mania (specific interventions not detailed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 11915580

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) 2.5 mg/24 h transdermal patches
Number of subjects: 24

Group type: COMPARATOR
Intervention: Diclofenac (DCF) 50 mg per os
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN)
Number of subjects: 24
Study: 10080605

Group type: EXPERIMENTAL
Intervention: Octreotide LAR 10 mg every 4 weeks
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Octreotide LAR 20 mg every 4 weeks
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Octreotide LAR 30 mg every 4 weeks
Number of subjects: 79

Group type: COMPARATOR
Intervention: Open-label SC octreotide every 8 hours
Number of subjects: 79
Study: 7747843

Group type: EXPERIMENTAL
Intervention: Rectal sodium diclofenac 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups (diclofenac and placebo)
Number of subjects: 0
Study: 8467273

Group type: EXPERIMENTAL
Intervention: Cue exposure (Group E)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cue exposure and cognitive aversion (Group E/CA)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Routine treatment alone (Group C)
Number of subjects: 21
Study: 2880690

Group type: EXPERIMENTAL
Intervention: Somatostatin-28 (SS-28)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Somatostatin-14 (SS-14)
Number of subjects: 8
Study: 31394282

Group type: EXPERIMENTAL
Intervention: Supervised progressive resistance training (36 sessions, 1 hour each, 3 times weekly for 12 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no change in daily activity level)
Number of subjects: 39
Study: 30153428

Group type: EXPERIMENTAL
Intervention: Integrated care (ABC group, n=222; 7%)
Number of subjects: 3169

Group type: COMPARATOR
Intervention: Non-ABC group (n=2947; 93%)
Number of subjects: 3169

Group type: EXPERIMENTAL
Intervention: Integrated care (ABC group)
Number of subjects: 3169
Study: 26813524

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD; 1250 kcal/day) for 12 weeks
Number of subjects: 57

Group type: COMPARATOR
Intervention: Very-low-calorie diet (VLCD; 500 kcal/day) for 5 weeks
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Very-low-calorie diet (VLCD; 500 kcal/day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Low-calorie diet (LCD; 1250 kcal/day)
Number of subjects: 57
Study: 24602167

Group type: EXPERIMENTAL
Intervention: Conventional restorations (CR)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Hall technique (HT)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Non-restorative caries treatment (NRCT)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control group (CR)
Number of subjects: 169
Study: 23446173

Group type: EXPERIMENTAL
Intervention: Low-intensity practical blood flow restriction (LI-pBFR)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (zero pressure wraps)
Number of subjects: 12
Study: 21335372

Group type: EXPERIMENTAL
Intervention: A1C cutoff of 5.9%
Number of subjects: 10038

Group type: EXPERIMENTAL
Intervention: A1C cutoff of 5.6%
Number of subjects: 10038

Group type: EXPERIMENTAL
Intervention: Baseline A1C ≥5.6%
Number of subjects: 10038
Study: 19156568

Group type: EXPERIMENTAL
Intervention: GHRH (100 microg as an intravenous bolus) with naloxone (2 mg bolus followed by 1.6 mg/h infusion)
Number of subjects: 11

Group type: COMPARATOR
Intervention: GHRH (100 microg as an intravenous bolus) without naloxone
Number of subjects: 11
Study: 16569097

Group type: EXPERIMENTAL
Intervention: Project SUPPORT intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing services condition (Control)
Number of subjects: 0
Study: 15273018

Group type: EXPERIMENTAL
Intervention: Positive feedback about performance on a verbal task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative feedback about performance on a verbal task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparative feedback (single or aggregated target)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Objective standard feedback
Number of subjects: 0
Study: 11074396

Group type: EXPERIMENTAL
Intervention: ss2-agonist
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: ss2-agonist and ICS
Number of subjects: 86
Study: 9512845

Group type: EXPERIMENTAL
Intervention: 0.54% hyperbaric lidocaine (48 mg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 0.3% hyperbaric lidocaine (72 mg)
Number of subjects: 43
Study: 7836703

Group type: EXPERIMENTAL
Intervention: High prolactin release (delta prolactin > 1000 mu u/ml, n = 11)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Low prolactin release (delta prolactin < 1000 mu u/ml, n = 8)
Number of subjects: 19
Study: 2975199

Group type: EXPERIMENTAL
Intervention: 100 mg dapsone daily for 16 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: 40 mg 13‐cis retinoic acid daily for 16 weeks
Number of subjects: 40
Study: 31400333

Group type: EXPERIMENTAL
Intervention: Moderate/severe atheroma grade (grade III-V)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Mild atheroma grade (grade I-II)
Number of subjects: 383
Study: 29756523

Group type: EXPERIMENTAL
Intervention: Health education by pharmacists (lifestyle intervention)
Number of subjects: 190
Study: 27038277

Group type: EXPERIMENTAL
Intervention: Laparoscopic right colectomy (LRC)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Laparoscopic-assisted colonoscopic polypectomy (LACP)
Number of subjects: 34
Study: 25204013

Group type: EXPERIMENTAL
Intervention: Magnesium lactate (360 mg elemental magnesium)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 22828734

Group type: EXPERIMENTAL
Intervention: Bovine colostrum
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (iso-energetic and iso-proteinaceous supplement)
Number of subjects: 12
Study: 20625131

Group type: EXPERIMENTAL
Intervention: Pyridoxine (200 mg/d)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Pyridoxine (for patients who developed grade 2 or worse HFS in the placebo group)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo (for patients who developed grade 2 or worse HFS in the placebo group)
Number of subjects: 360
Study: 18794505

Group type: EXPERIMENTAL
Intervention: Functional relaxation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 16789505

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD) patients
Number of subjects: 20
Study: 12439645

Group type: EXPERIMENTAL
Intervention: Ephedrine and caffeine (20/200 mg, three times daily) for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hypoenergetic diet (70% of energy expenditure)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (untreated obese subjects)
Number of subjects: 0
Study: 9101609

Group type: EXPERIMENTAL
Intervention: Low-osmolality contrast medium (ioxaglic acid - Hexabrix)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (renal donors)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Patients with diseases of multiple etiologies
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Moderate renal function deficit (CrCl 25 to 60 mL/min)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Mild renal function deficit (CrCl >= 60 mL/min)
Number of subjects: 39
Study: 2779901

Group type: EXPERIMENTAL
Intervention: Antibiotic regimens in the trial
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pretrial patients
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Trial patients
Number of subjects: 50
Study: 1105628

Group type: EXPERIMENTAL
Intervention: Imipramine treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ECT treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probenecid administration
Number of subjects: 0
Study: 31829287

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 933

Group type: COMPARATOR
Intervention: Everolimus (comparator arm)
Number of subjects: 933
Study: 27562843

Group type: EXPERIMENTAL
Intervention: Unilateral dynamic knee-extension exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: α-fluoromethylhistidine hydrochloride (α-FMH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: H1/H2-receptor blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0